linkedin

Press Releases

Life @ Samsung Biologics

Together We Save Lives

Together We Save Lives

 

 

At Samsung Biologics, we have a shared commitment to saving the lives of people around the globe through high-quality biomedicines. Our recent 'Together, We'  brand video together, we series highlights our mission to offer one-of-a-kind service offerings the unique strengths we hold at Samsung Biologics.   

 

 

Together, We

 

Together, We series represents our competitive edge to offer unprecedented ‘Speed’, ‘Quality’, and ‘Innovation’ showcased through different motions of pace-maker, orchestra, and space explorers. 

 

 

For Greater Speed - Together We Advance


2?%201%20Together%20we%20advance.jpg

The one thing you need to improve your pace

is a strong partner.

 


For The Best Quality - Together We Improve


2?%202%20Together%20we%20improve.jpg


The one thing you need to perform your masterpiece

is a world-class orchestra.

 

 

For Innovation Solution – Together We Achieve


2?%203%20Together%20we%20achieve.jpg

The one thing you need to find new ways

is a partner who takes the leap.


 

Speed, Quality, and Innovation


Together with our teams of experts, we take our clients on a journey they have never taken before to accomplish our shared goals through agile, high-quality, and innovative solutions to ultimately save the lives of humanity and build a healthier future for humanity. 

 

2?%204.jpg
 

2?%205.jpg
 

2?%206.jpg
 

Since our establishment in 2011, we have continued to evolve to ensure that we provide the highest quality services to our clients and we do this through our dedication to continuous innovation and ensure speed and quality across all value chains. 


We broke ground to Plant 4 last year which upon completion will break our own record of holding the world’s largest biomanufacturing capacity of 620,000L at a single site. We also opened up a global R&D Center in South San Francisco at the heart of the fastest developing biocluster to provide immediate convenience to global clients. Additionally, we launched our proprietary cell line S-CHOice® and process development platform S-CellerateTM which both enable Samsung Biologics’ team to provide more competitive and innovative service offerings to clients, ultimately accelerating the speed of molecules to market whilst ensuring the highest quality of products. 


In light of the pandemic, the company has also been proactive in accommodating client needs in the biopharma CDMO landscape, including its plans to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. 


In the field of digitalization, Samsung Biologics continues to embrace and leverage the latest technology to enhance client experience. We introduced our Virtual Exhibition Hall which through an immersive and interactive experience enabled by photorealistic 3D modeling, visitors are able to view our business services and facilities, and have richer conversations with our team of experts. We also implemented the Live Virtual Tour (LVT) to allow for global clients to access our facilities via a live-streaming platform and take a scheduled tour, audit, or inspection at their convenience. The platform also leverages a global on-demand cloud infrastructure to optimize speed and connectivity for clients and regulatory bodies from any location. 


Through collaborative efforts and continuous improvements in our facility and service offerings, we will continue to advance forward with ‘Speed’, ‘Quality’, ‘Innovation’ as our core values and help build a better future for humanity. 


 

  

Related Contents


Life @ Samsung Biologics It's in our DNA

Press Releases GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

Samsung BIO Insight  Samsung Biologics at BIO Digital 2021

Together We Save Lives

 

 

At Samsung Biologics, we have a shared commitment to saving the lives of people around the globe through high-quality biomedicines. Our recent 'Together, We'  brand video together, we series highlights our mission to offer one-of-a-kind service offerings the unique strengths we hold at Samsung Biologics.   

 

 

Together, We

 

Together, We series represents our competitive edge to offer unprecedented ‘Speed’, ‘Quality’, and ‘Innovation’ showcased through different motions of pace-maker, orchestra, and space explorers. 

 

 

For Greater Speed - Together We Advance


2?%201%20Together%20we%20advance.jpg

The one thing you need to improve your pace

is a strong partner.

 


For The Best Quality - Together We Improve


2?%202%20Together%20we%20improve.jpg


The one thing you need to perform your masterpiece

is a world-class orchestra.

 

 

For Innovation Solution – Together We Achieve


2?%203%20Together%20we%20achieve.jpg

The one thing you need to find new ways

is a partner who takes the leap.


 

Speed, Quality, and Innovation


Together with our teams of experts, we take our clients on a journey they have never taken before to accomplish our shared goals through agile, high-quality, and innovative solutions to ultimately save the lives of humanity and build a healthier future for humanity. 

 

2?%204.jpg
 

2?%205.jpg
 

2?%206.jpg
 

Since our establishment in 2011, we have continued to evolve to ensure that we provide the highest quality services to our clients and we do this through our dedication to continuous innovation and ensure speed and quality across all value chains. 


We broke ground to Plant 4 last year which upon completion will break our own record of holding the world’s largest biomanufacturing capacity of 620,000L at a single site. We also opened up a global R&D Center in South San Francisco at the heart of the fastest developing biocluster to provide immediate convenience to global clients. Additionally, we launched our proprietary cell line S-CHOice® and process development platform S-CellerateTM which both enable Samsung Biologics’ team to provide more competitive and innovative service offerings to clients, ultimately accelerating the speed of molecules to market whilst ensuring the highest quality of products. 


In light of the pandemic, the company has also been proactive in accommodating client needs in the biopharma CDMO landscape, including its plans to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. 


In the field of digitalization, Samsung Biologics continues to embrace and leverage the latest technology to enhance client experience. We introduced our Virtual Exhibition Hall which through an immersive and interactive experience enabled by photorealistic 3D modeling, visitors are able to view our business services and facilities, and have richer conversations with our team of experts. We also implemented the Live Virtual Tour (LVT) to allow for global clients to access our facilities via a live-streaming platform and take a scheduled tour, audit, or inspection at their convenience. The platform also leverages a global on-demand cloud infrastructure to optimize speed and connectivity for clients and regulatory bodies from any location. 


Through collaborative efforts and continuous improvements in our facility and service offerings, we will continue to advance forward with ‘Speed’, ‘Quality’, ‘Innovation’ as our core values and help build a better future for humanity. 


 

  

Related Contents


Life @ Samsung Biologics It's in our DNA

Press Releases GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

Samsung BIO Insight  Samsung Biologics at BIO Digital 2021

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved